anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A medical imaging system is provided. The medical imaging system may include a mobile device configured to remotely control a medical imaging device. The medical imaging device may include a scanner, a control module, and a second communication port. The second communication port may be configured to receive an instruction from the mobile device via a network. The scanner may scan the object and generate scanning data related to the object in response to a scan instruction received by the second communication port from the mobile device via the network. The control module may control movement of at least one of the gantry of the scanner or the scanning table in response to a control instruction received by the second communication port from the mobile device via the network.
Alpha-aryl-alpha-pyridyl alkanoic acid derivs. of formula (I) and their salts are prepd. by the hydrolysis of cpds. of formula (II). In (I), R1 is cyano or carbamoyl; R2 is H or Halo; R3 is H or lower alkyl; one of R4 and R5 is lower alkyl and the other is H; R6 and R7 are each lower alkyl or together completes piperazinyl gp. opt. substd. by lower alkyl. (I) have antiulcer and spasmolytic activity and are useful for treating ulcers and spasms.
In controlled clinical trials, the most frequent adverse reactions reported for clobetasol propionate cream were burning and stinging sensation in 1% of treated patients. Less frequent adverse reactions were itching, skin atrophy, and cracking and fissuring of the skin.

Cushing syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations.

The following additional local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: dryness, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.

To report SUSPECTED ADVERSE REACTIONS, contact Xiromed, LLC at 1-844-XIROMED (1-844-947-6633) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Participants in the experimental group will receive one active individual music therapy session each week for 22 weeks. Each session will last thirty minutes.
The present invention relates to a pharmaceutical composition in the form of a powder comprising amoxicillin, cineol and a pharmaceutically acceptable oil. The present formulation can also include clavulanic acid. The formulation is intended to be administered orally, preferably following suspension in an aqueous solvent. The present invention also relates to a combination of cineol and amoxicillin for use in the treatment of an infectious disease, preferably a bacterial infection, in a subject. The present combination can also include a ß-lactamase inhibitor, preferably clavulanic acid. The combination according to the invention can be used in particular to fight infections caused by bacteria resistant to antibiotics, preferably to antibiotics of the ß-lactam family.
INTRODUCTION: Systemic and local therapies for patients with metastatic renal cell carcinoma (mRCC) are often challenging despite the evolution of multimodal cancer therapies in the last decade. In this review, we will focus on recent multidisciplinary approaches for patients with mRCC.
AREAS COVERED: Systemic therapies for patients with mRCC have been garnering attention particularly after the approval of immuno-oncology (IO) agents, including anti-programmed death 1/programmed death-ligand 1. IO combinations have significantly prolonged overall survival in patients with mRCC in the first-line setting. Regarding local therapies, cytoreductive nephrectomy (CN) has become less common in the post-Cancer du Rein Metastatique Nephrectomie et Antiangiogéniques (CARMENA) trial era, even though CN may still benefit selected patients with mRCC. In addition, metastasis-directed local therapies, namely metastasectomy or stereotactic radiotherapy, particularly for oligo-metastatic lesions or brain metastases, may have a prognostic impact. Several ablative techniques are also evolving while maintaining high local control rates with acceptable safety.
EXPERT OPINION: Multimodal cancer therapies are essential for conquering complex cases of mRCC. Modern systemic therapies including IO-based combination therapy as well as local therapies including CN, metastasectomy, stereotactic radiotherapy, and ablative techniques appear to improve oncologic outcomes of patients with mRCC, although appropriate patient selection is indispensable.
This is a double-blind (neither physician nor participants knows the treatment that the participant receives), placebo-controlled (placebo is compared with the study medication to test whether the study medication has a real effect in clinical study), randomized (the study medication is assigned by chance) 4-way crossover (method used to switch participants to 4 different arms in a clinical study), and a single dose study. This study will consist of a screening phase (between 28 to 2 days prior to the study medication), a treatment phase of 4 double blind study periods (2 days), and a follow-up phase (within 7 to 14 days after last dose of the study medication). Approximately 20 participants with major depressive disorder will participate in this study. Participants will be randomly assigned to 1 of 4 cohorts (groups) (Cohorts A, B, C, and D) to receive JNJ-42847922 (10 mg, 20 mg, and 40 mg) and placebo. Each cohort consists of 4 treatment periods (Periods 1, 2, 3, and 4). Safety will be evaluated by the assessment vital signs, 12-lead electrocardiogram, clinical laboratory testing, physical examination, and neurological examination. The total duration of study participation for a participant will be approximately 9 to 10 weeks.
The efficacy of MYCAPSSA was established in a 9 month, randomized, double-blind, placebo-controlled study (NCT03252353) that enrolled 56 patients with acromegaly.

In the overall study population, 54% were female and the average age of patients was 55 years. 91% of patients were Caucasian, 5% Asian, 2% Black, and 2% Other. The percentage of patients with previous pituitary surgery was 88%. The baseline IGF-1 levels (the average of 2 assessments measured within 2 weeks of randomization) was 0.80 times ULN (range: 0.5–1.1 times ULN) in the patients treated with MYCAPSSA and 0.84 times ULN (range: 0.3–1.1 times ULN) in patients treated with the placebo.

In this study, patients initiated MYCAPSSA treatment twice daily 1 month after their last injection of somatostatin analogs. The starting dose was 40 mg (20 mg in the morning and 20 mg in the evening). Dose increase was allowed during dose titration to 60 mg (40 mg in the morning and 20 mg in the evening) and to a maximal dose of 80 mg daily (40 mg in the morning and 40 mg in the evening) until patients were deemed adequately controlled based on biochemical results and/or clinical judgement. Patients then maintained their target dose until end of treatment.

The primary efficacy endpoint was somatostatin dose-adjusted proportion of patients who maintain their biochemical response, defined as an IGF-1 levels less than or equal to the ULN at the end of 9 months of treatment. 58% of patients treated with MYCAPSSA vs. 19% of patients treated with placebo maintained their biochemical response.

25% of patients treated with MYCAPSSA required discontinuation of MYCAPSSA and treatment with other somatostatin analogs at some point during the 9-month study. Criteria for somatostatin analog rescue were IGF-1 levels ≥ 1.3 times ULN and exacerbation of acromegaly signs and symptoms on two consecutive assessments while treated for at least 2 weeks with 80 mg/day or other reasons such as adverse reactions or patient's decision.
Methods for the treatment and prevention of APP processing disorders such as Alzheimer's disease and Down's Syndrome which are based on the administration of an effective amount of a HMG-CoA reductase inhibitor to a mammal are disclosed. Additionally, methods for the treatment and prevention of APP  processing disorders such as Alzheimer's disease and Down's Syndrome which are based on the reduction of cellular cholesterol in a mammal are disclosed.  These methods reduce the amount of A.beta. peptides or decrease the formation of A.beta. peptides or increase the clearance of A.beta. peptides in a mammal suffering from Alzheimer's disease and Down's Syndrome.
OBJECTIVE: Pediatric nonalcoholic fatty liver disease (NAFLD) is a growing problem, but its underlying mechanisms are poorly understood. We used transcriptomic reporter cell assays to investigate differences in transcriptional signatures induced in hepatocyte reporter cells by the sera of children with and without NAFLD.
METHODS: We studied serum samples from 45 children with NAFLD and 28 children without NAFLD. The sera were used to induce gene expression in cultured HepaRG cells and RNA-sequencing was used to determine gene expression. Computational techniques were used to compare gene expression patterns.
RESULTS: Sera from children with NAFLD induced the expression of 195 genes that were significantly differentially expressed in hepatocytes compared to controls with obesity. NAFLD was associated with increased expression of genes promoting inflammation, collagen synthesis, and extracellular matrix remodeling. Additionally, there was lower expression of genes involved in endobiotic and xenobiotic metabolism, and downregulation of peroxisome function, oxidative phosphorylation, and xenobiotic, bile acid, and fatty acid metabolism. A 13-gene signature, including upregulation of TREM1 and MMP1 and downregulation of CYP2C9, was consistently associated with all diagnostic categories of pediatric NAFLD.
CONCLUSION: The extracellular milieu of sera from children with NAFLD induced specific gene profiles distinguishable by a hepatocyte reporter system. Circulating factors may contribute to inflammation and extracellular matrix remodeling and impair xenobiotic and endobiotic metabolism in pediatric NAFLD.
Radiation to 45-50.4 Gy, 5 x per week, 1.8Gy/fx. Radiation begun the day after the first dose of anti-PD-1 antibody . Anti-PD-1 antibody (every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 30 minutes.
NEW MATERIAL:A cyclic sulfoxide derivative of formula I (R<1> is H, lower alkyl or lower alkenyl; R<2> is >=8C hydrocarbon group; n is 1-4). EXAMPLE:2-Hexadecyltetramethylene sulfoxide. USE:A drug. A percutaneous absorption-accelerating agent. The drug or agent is preferably applied directly to an injured portion of a near portion thereof for the total treatment of an injury, skin sore, muscle pain, arthritis, etc., or applied to an easily medical ingredient-absorbing site for the general treatment of organs, etc., in the body. The agent is further used in cosmetics for skin cleansing, face packing, sunburn measures, skin irritation measures, moisture treatment, etc. PREPARATION:A cyclic sulfoxide of formula II is reacted with an alkylating agent of formula: R<5>X (X is halogen, tosyloxy, mesyloxy or trifluoromethanesulfonyloxy) preferably in a solvent such as tetrahydrofuran in the presence of a base such as NaH to readily provide the compound of formula I.
ABSTRACT OF THE DISCLOSURE Serological method for determining the presence of Neisseria gonorrhoeae antibodies in human sera and products utilized in such test.  A composition containing serum is in-cubated with a composition containing a species specific antigen preparation produced from a growth culture of Neisseria gonorrhoea to form an antigen-antibody conjugate when said antibodies are present.  The presence of the conjugate it then detected.  The antigen is protein in nature, is stable in boiling water for a period of one hour, and is stable when incubated with the follow-ing enzymes:  DNA ase,  RNA ase,  dextransase, neuraminidase, and lysozyme.  Also the antigen has an isoelectric point of 4 + .2 and a molecular weight of active subunits of 37,000 40,000 as determined by SDS-polyacrylamide gel, contains 2-3% organic phos-phorous, and is soluble in aqueous media containing surface active agents and insoluble in methanol, chloroform, and acetone.  The method of preparing the antigen preparation may include removing contaminates by precipitation of proteins with trichloroacetic acid and ultrafiltration to remove the carbohydrate.
PURPOSE:To obtain the titled composition containing calcitonins as active ingredient and 1-dodecylazacycloheptane-2-one emulsified by a surfactant as an absorbefacient agent, having good absorbing properties and providing no lesion to mucous membrane of nasal cavity. CONSTITUTION:A calcitonin pharmaceutical for dermal administration containing 0.1-5W/V% 1-dodecylazacycloheptane-2-one as an absorbefacient agent. Since calcitonins are peptides having serum calcium lowering action, it is used as a remedy to hypercalcemia, vitamin D intoxication, metabolic bone disease, etc., and hydrolyzed by digestive enzyme. Therefore, the composition for dermal administration is practical pharmaceutical being more simple and capable of administering by patient itself. Since the above-mentioned absorbefacient agent is insoluble in water, it is preferably modified to emulsion using a nonionic surfactant (e.g. polyoxyethylenesorbitane fatty acid esters).
Effective respiratory function is crucial for swimmers, given the demanding nature of the sport. Inspiratory muscle training (IMT) has been shown to improve respiratory muscle strength and endurance in various populations. This study aims to explore the effects of IMT specifically on competitive swimmers, assessing both physiological and performance-related outcomes. To assess whether a structured IMT program improves swimming performance, respiratory muscle strength, and overall respiratory efficiency in recreational swimmers. A randomized controlled trial involving 56 competitive swimmers will be conducted. The study duration will be 8 weeks, with assessments conducted at baseline, mid-point, and at the end of the intervention. The IMT groups will participate in a 20-30 minute training session, 4 to 5 times per week, using power breath device . The training will focus on enhancing inspiratory muscle strength and endurance. This study aims to provide robust evidence on the benefits of IMT for swimmers, potentially informing future training practices and enhancing competitive performance.
The safety and efficacy of Prograf in pediatric kidney and heart transplant patients have not been established. Successful liver transplants have been performed in pediatric patients (ages up to 16 years) using Prograf. Two randomized active-controlled trials of Prograf in primary liver transplantation included 56 pediatric patients. Thirty-one patients were randomized to Prograf-based and 25 to cyclosporine-based therapies. Additionally, a minimum of 122 pediatric patients were studied in an uncontrolled trial of tacrolimus in living related donor liver transplantation. Pediatric patients generally required higher doses of Prograf to maintain blood trough concentrations of tacrolimus similar to adult patients [see Dosage and Administration (2.2)].
PURPOSE: To obtain an immunopotentiator, having high anticomplementary activities, activating actions on macrophage functions, bacterial phylactic actions, etc., and producible at a low cost. CONSTITUTION: This immunopotentiator contains a proteinic ingredient extracted from a yeast cell with an alkali as an active ingredient. The yeast cell used is preferably a Torula yeast or a Saccharomyces yeast from the viewpoint of easy availability of raw materials and a yeast cultured in a sulfite pulp waste liquor culture medium is especially optimal due to its low cost and further high activities. The yeast is preferably extracted with the alkali under conditions of 0.1-20wt.%, preferably 0.1-13wt.% yeast concentration, 0.1-10wt.% alkali concentration, 10-70 deg.C extraction temperature and 10min to 48hr extraction time. The resultant alkali extract is then neutralized. The neutralized extract, together with the extraction residue, is concentrated and dried or the supernatant after removing the extraction reside is concentrated and dried to afford the immunopotentiator.  When the alkali extract is used together with the extraction residue, the content of proteins in the extract is preferably >=10wt.% based on the protein in the yeast cell. The immunopotentiator is useful for potentiating the biophylactic abilities of crustaceans and fishes and blended in an amount of 0.05-10wt.% in a feed.
Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
Safety for the use of chlorpromazine during pregnancy has not been established. Therefore, it is not recommended that the drug be given to pregnant patients except when, in the judgment of the physician, it is essential. The potential benefits should clearly outweigh possible hazards. There are reported instances of prolonged jaundice, extrapyramidal signs, hyperreflexia or hyporeflexia in newborn infants whose mothers received phenothiazines.

Reproductive studies in rodents have demonstrated potential for embryotoxicity, increased neonatal mortality and nursing transfer of the drug. Tests in the offspring of the drug-treated rodents demonstrate decreased performance. The possibility of permanent neurological damage cannot be excluded.

### Non-teratogenic Effects

Neonates exposed to antipsychotic drugs, during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery. There have been reports of agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress and feeding disorder in these neonates. These complications have varied in severity; while in some cases symptoms have been self-limited, in other cases neonates have required intensive care unit support and prolonged hospitalization.

Chlorpromazine hydrochloride should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The present invention relates to photo-activated disinfection. In particular, the present invention relates to photo-activated disinfection in the oral cavity. We describe a dental apparatus comprising a light source producing light at a predetermined wavelength and power, and optical transmission means to train the light from the light source onto at least one external side of a tooth. Preferably, the optical transmission means comprises at least one optical guide. In a preferred embodiment, the optical transmission means comprises a pair of substantially parallel elongate light guides each light guide having a distal end provided with a reflective surface inclined at 45° to the direction of light transmission along the light guides, the reflective surfaces of the light guides being opposed such that light emitted from each light guide is parallel but opposite in direction. Preferably, the light source is a light emitting diode or array of light emitting diodes and the has a wavelength of from 550 to 690 nm, more preferably from 600 nm to 680 nm, even more preferably from 625 to 660 nm.
The overall goal of this project is to address the postulate that the optimal molecular signature for the common disorder obstructive sleep apnea (OSA) is change in relevant biomarkers during the sleep period. In sleep apnea, events lead to sleep fragmentation and cyclical deoxygenation/reoxygenation. It is proposed that these changes will lead to molecular consequences can be detected by assessing biomarkers in blood. To determine which changes are due to OSA and which to circadian/sleep mechanisms, studies will be done in patients with OSA before and after effective treatment with Continuous Positive Airway Pressure (CPAP) and also in controls of similar visceral adiposity without OSA. Multiple assessments of biomarkers will be made before, during and after sleep. Since it is proposed that the magnitude of these dynamic changes across the sleep period will be affected by degree of visceral obesity and be greater in OSA subjects with cardiovascular comorbidities, studies will be done in 4 groups of subjects: lean and obese with and without such morbidities. In assessing biomarkers the primary outcome variables will be: urinary isoprostanes (oxidative stress); plasma tumor necrosis factor alpha (TNFα) (inflammation); plasma norepinephrine (sympathetic activation); and free fatty acids. Secondary biomarkers will be: Interleukin 6 (IL-6), urinary norepinephrine; urinary normetanephrine; glucose, Intercellular Adhesion Molecule (ICAM), leptin. To complement assessment of circulating biomarkers, an approach utilizing a cellular window will be used. Monocytes will be separated from each blood sample (before, during and after sleep) and RNA extracted. Expression of key genes will be assessed by RT-PCR and microarray studies will be performed in a subset of subjects to assess changes in expression of all genes as a result of OSA. A particular focus will be investigating differences between individuals with OSA with and without cardiovascular comorbidities. Three aspects will be evaluated: a)whether individuals with comorbidities have more oxidative stress and inflammatory change for equivalent degrees of OSA than individuals without such comorbidities; b) whether individuals with comorbidities have lower levels of protective mechanisms-melatonin (an anti-oxidant secreted during sleep), IL-10 (antiinflammatory); c) different gene variants based on a genetic association study using a recently developed CV SNP array. Finally, data will be used to determine whether there is a diagnostic urine and/or blood test for OSA.
The aim of this study was to verify the association of the ACTN3-R577X polymorphism with sarcopenia stage, according to the Revised European Consensus on the Definition and Diagnosis of Sarcopenia, in middle-aged and older adults, pre- and post- ST. In the 12-week longitudinal study, 71 middle-aged and older adults were evaluated; the participants were assigned to either control or intervention group. The intervention group underwent progressive ST three times a week. All participants underwent blood collection, DNA extraction, genotyping of the ACTN3-R577X polymorphism, anthropometric evaluations, and diagnostic tests for sarcopenia. The last two tests were repeated after 12 weeks. No association of the ACTN3-R577X polymorphism with sarcopenia stage was observed before and after 12 weeks. However, the intervention group remained non-sarcopenic (n = 25, p <0.05) or achieved changes in sarcopenia stage (from sarcopenic to non-sarcopenic) (n = 13, p <0.05). Our study demonstrates that progressive ST performed regularly can reverse or prevent sarcopenia regardless of genotype for the ACTN3-R577X polymorphism.
All individuals will receive study treatment in the same sequence. Period 1 (Days 1 to 4) consists of a single oral dose of 1000 mg abiraterone acetate tablets on Day 1 only. Period 2 (Days 11 to 17) consists of a daily oral dose of 400 mg ketoconazole tablets on Days 11 to 16 and administration of a single dose of 1000 mg abiraterone acetate on Day 14.